• Free for qualified executives and consultants to industry

  • Receive quarterly issues of Area Development Magazine and special market report and directory issues


GenScript USA Opens Piscataway, New Jersey, Operations Campus

GenScript USA Inc., a leading life science research tools and services provider, opened a more than 50,000-square-foot facility near its U.S. headquarters in Piscataway, New Jersey.

According to company officials, the new facility is GenScript's first automated manufacturing site in the U.S. and represents a 10-fold increase in capacity, enabling it to better serve local customers, and expand its customer base in the region and nationwide.

"GenScript is extremely committed to supporting our customers as they expand globally, and this specialized laboratory and manufacturing facility allows us to deliver reliable products to them faster than ever before," said Ray Chen, PhD, president of GenScript USA Life Science Group, Inc. "Importantly, this site also gives our U.S. customers additional production resilience in case of unexpected events, such as pandemics and changes in customs and trade regulations."

The state-of-the-art site marks a significant expansion of the company's advanced gene synthesis services, and is designed to mitigate U.S-based customers' supply chain risks with high quality, fast-turnaround on products required for new vaccines, therapeutics and innovations in synthetic biology.

"We are fortunate to be located in an area where this in an abundance of talent and expertise," added Chen. "With this facility, we also intend to add 100-200 jobs in research and manufacturing over the next two years."

A pioneer in the field of DNA synthesis, GenScript said it has completed more than 600,000 gene synthesis projects for scientists globally. Its patented gene synthesis and plasmid preparation services offer small laboratories and large commercial organizations innovative and high-quality products for developing cell and gene therapies for cancer and other diseases, and new vaccines.

Exclusive Research